COVID-19 – How What You Flush Can Help Scientists Measure Community Health

Posted on Sat/2/MaySat/2/May by AZBio

Fighting Coronavirus/COVID-19 with Public Health Data

The City of Tempe and Arizona State University are working together to study wastewater as a strategy to advance community health. Tempe is in a unique position for an innovative response to the coronavirus/COVID-19 pandemic due to the Wastewater Data Analytics – Opioids program supported by the Tempe City Council’s Innovation Fund in 2018 and the community trust cultivated by the city’s compassion, science and services approach in using public health data. Continue reading→

CDC launches national viral genomics consortium to better map SARS-CoV-2 transmission

Posted on Fri/1/MaySat/2/May by AZBio

Rapid release of open coronavirus sequence data will help guide COVID-19 public health response, drive innovation and discovery, and advance understanding of this and future pandemics.

The SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance (SPHERES) consortium, which will greatly expand the use of whole genome sequencing (WGS) of the COVID-19 virus. Consortium members include Northern Arizona University, TGen, and the State of Ariona.

Continue reading→

RESONEA Selected for Flinn Foundation Bioscience Entrepreneurship Program

Posted on Fri/1/MayMon/4/May by AZBio

Funding Will Support Commercialization of DROWZLE® PRO, the First FDA-Cleared Digital Home Sleep Test, and Consumer Sleep Health PlatformContinue reading→

FDA Issues Emergency Use Authorization for Remdesivir

Posted on Fri/1/MayFri/1/May by AZBio

Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 TreatmentContinue reading→

Medtronic COVID-19 Care Evaluation and Monitoring Solution Provides Support to Healthcare Providers and Patients

Posted on Fri/1/MayMon/4/May by AZBio

The Medtronic COVID-19 Care Evaluation and Monitoring Solution provides in-home evaluation, remote monitoring, and care escalation support.

Continue reading→

Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus

Posted on Fri/1/MayFri/1/May by AZBio

Collaboration goal to enable manufacturing of up to 1 billion doses per year
Technology transfer expected to begin in June 2020
First batches of mRNA-1273 expected to be manufactured at Lonza U.S. in July 2020
Collaboration leverages Lonza’s worldwide expertise in technology transfer and manufacturing

Continue reading→

Valneva and Pfizer Announce Collaboration to Co-develop and Commercialize Lyme Disease Vaccine, VLA15

Posted on Thu/30/AprilMon/4/May by AZBio

VLA15 is the only active Lyme disease vaccine program in clinical development today, and covers six serotypes that are prevalent in North America and Europe. The investigational multivalent protein subunit vaccine, VLA15, targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for a Lyme disease vaccine. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.Continue reading→

Gilead Sciences Chairman & CEO Shares Open Letter on Remdesivir Data

Posted on Wed/29/AprilWed/29/April by AZBio

On April 29, 2020, Daniel O’Day, Chairman & CEO, Gilead Sciences shared an Open Letter following the official press release containing data on Remdesivir and COVID-19.

“The results from the global, placebo-controlled trial run by the National Institute of Allergy and Infectious Diseases (NIAID) are positive. They show that patients with COVID-19 who received remdesivir recovered faster than similar patients who received placebo” O’Day writes. “There is still more work to do and remdesivir has not been approved, but all of us at Gilead are humbled by what these promising results might mean for patients. After years of research and hard work on remdesivir, there is relief and gratitude among our teams today that their efforts have been so worthwhile.”

Continue reading→

Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19

Posted on Wed/29/AprilWed/29/April by AZBio

Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of RemdesivirContinue reading→

Dr. Theresa Cullen to join Pima County team as Public Health Director on June 1

Posted on Wed/29/AprilFri/1/May by AZBio

Dr. Theresa Cullen is the new Pima County Public Health Director, effective June 1. Dr. Cullen has had a distinguished career as a public health physician, including retiring as a Public Health Service Officer from the federal government with the rank of Rear Admiral and Assistant U.S. Surgeon General.

Continue reading→